News & Updates

Alirocumab administered every 2 or 4 weeks (Q2W or Q4W) significantly reduced low-density lipoprotein-cholesterol (LDL-C) levels in paediatric patients with heterozygous familial hypercholesterolaemia (HeFH), according to a study presented at ESC 2023.

Brain disorders – comprising mental illness, neurologic conditions, and stroke – account for over 15 percent of global health loss (how much healthy life is lost due to early death, illness, or ability) in the Global Burden of Disease (GBD) study presented at EAN 2023.

The International Society of Hypertension (ISH) has recently put out a position paper that addresses lifestyle management of hypertension. The paper is endorsed by the World Hypertension League and European Society of Hypertension. [DOI:10.1097/HJH.0000000000003563]

Catheter ablation boosts outcomes in patients with advanced heart failure (HF) who are being considered for heart transplantation or left ventricular assist device (LVAD) implantation in the CASTLE-HTx trial presented at ESC 2023.

Single-ventricle physiology appears to predict higher short-term mortality among adult transplant recipients with coronary heart disease (CHD), suggests a study.

Extended clopidogrel monotherapy after a 9- to 12-month course of dual antiplatelet therapy (DAPT) reduces bleeding and ischaemic events in patients with acute coronary syndrome (ACS) who are at high risk for both events, according to the OPT-BIRISK* trial presented at ESC 2023.